DocDollars

Biohaven Pharmaceuticals, Inc.

CT · United States · Reporting entity ID 100000806824

Total reported 2019–2025
$48.6M
#177 of 2,960 reporting companies — 0.1% of all reported industry payments
$13.7M in general payments across 188,414 records, plus $34.9M in research funding across 4,706 records.

How it breaks down

General payments $13,739,869
Research funding $34,896,216

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Biohaven Pharmaceuticals, Inc. reported $48.6M to US doctors and teaching hospitals from 2019 to 2025, ranking #177 of 2,960 reporting companies. 72% of that was research funding and 28% general payments such as consulting, speaking, food and travel. 188,414 general payment records and 4,706 research records were filed.

Common questions about Biohaven Pharmaceuticals, Inc.

How much has Biohaven Pharmaceuticals, Inc. paid US doctors?

Biohaven Pharmaceuticals, Inc. reported $48,636,085 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $13,739,869 in general payments, $34,896,216 in research funding.

How does Biohaven Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #177 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Biohaven Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.